City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: Many men’s health issues are either entirely preventable ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...

For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its ...

An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.

A new trial found that a progesterone-mimicking drug used to manage hot flashes and other symptoms may have anticancer ...

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Communications , identifies a powerful strategy to overcome drug resistance in ...

Rīga Stradiņš University (RSU) will host the BFCS 2026 international conference on 19–20 March 2026 in Riga, Latvia, in collaboration with the Baltic Flow Cytometry Society. The two-day event will ...